Breaks Categories: News

ThursdayDec 02, 2021 11:32 am

NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that subsidiary Ketamine Wellness Centers (“KWC”) is planning to open new clinics in Salt Lake City, Utah, and Reno, Nevada; the clinics are slated to open by February 2022. The new clinics will bring the total of KWC locations to 12; the company currently has 10 ketamine infusion treatment clinics in eight different states and is positioned as the largest chain of wellness centers in the country. The Utah location will be one of KWC’s largest clinics, and the Reno clinic is strategically…

Continue Reading

ThursdayDec 02, 2021 10:30 am

NetworkNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Receives Initial Orders from Mexico, Spain

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is expanding internationally. The company’s Flora Beauty division received its first-ever orders for its Mind Naturals and Awe CBD skincare brands for the Spanish and Mexican markets; the company plans to ship the product this month. Flora Beauty’s Mind Naturals brand is designed with young consumers who are just starting a skincare routine while its the AWE brand targets consumers who value customized and personal experiences. The Mind Naturals line was recently named a top-12 finalist in a global pitch competition sponsored by Glosswire. The…

Continue Reading

ThursdayDec 02, 2021 10:01 am

NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

Continue Reading

ThursdayDec 02, 2021 9:27 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting in the upcoming Stifel GMP second annual Future of Healthcare Conference. The conference, which is slated for Dec. 8, 2021, will include a presentation by Cybin CEO Doug Drysdale. According to the announcement, Drysdale’s presentation is scheduled to start at 3:30 p.m. ET. Following the presentation, interested viewers can view an archived version of the webcast on Cybin’s investor relations website. Cybin is working to create safe and effective therapeutics for patients to address a multitude of mental health issues. To view the…

Continue Reading

ThursdayDec 02, 2021 8:30 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. “Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin, which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models,” said Dr. Lakshmi P. Kotra,…

Continue Reading

WednesdayDec 01, 2021 2:39 pm

NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. The study, which is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D., will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of comorbidities that include anxiety, depression, poor sleep quality and other conditions. Tryp expects to initiate the study in 2022, subject to a favorable…

Continue Reading

WednesdayDec 01, 2021 2:28 pm

NetworkNewsBreaks – DeepMarkit Corp. (TSX.V: MKT) (OTC: MKTDF) Announces LOI for Acquisition of First Carbon Corp., Concurrent Private Placement

DeepMarkit (TSX.V: MKT) (OTC: MKTDF) recently announced its entry into a non-binding letter of intent (“LOI”) to acquire all of the issued and outstanding shares of First Carbon Corp. (“FCC”). The LOI sets forth the general terms and conditions of the acquisition, pursuant to which FCC shareholders will receive an aggregate of approximately 15,000,000 common shares of DeepMarkit (“common shares”), each issued at a deemed price of $0.50, for deemed consideration of approximately $7,500,000 (the “acquisition”). In addition, DeepMarkit announced a non-brokered private placement. Under the private placement, subject to acceptance by the TSX Venture Exchange, DeepMarkit intends to issue,…

Continue Reading

WednesdayDec 01, 2021 2:01 pm

NetworkNewsBreaks – SRAX Inc. (NASDAQ: SRAX) to Deconsolidate BIGtoken Inc. (FPVD) Following Merger

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has announced that, from this date forward, it will no longer have to consolidate the financials of BIGtoken (OTC: FPVD). On Sept. 27, 2021, BIGtoken, the leading platform for ethically-sourced identity, data and insights creation and media activation, and BritePool Inc., a leading identity verification company for advertisers and publishers, entered into an agreement and plan of merger in an all-stock transaction. Upon completion of the union, SRAX is no longer obligated to consolidate BIGtoken into its financials.…

Continue Reading

WednesdayDec 01, 2021 1:34 pm

NetworkNewsBreaks – Social Media Strategies Summit to Host Public Agencies, Government Offices Event

Social Media Strategies Summit, which is created by conference production company Global Strategic Management Institute, has announced its upcoming all-digital Social Media Strategies Summit – Public Agencies & Government event. The summit aims to aid government agencies in utilizing social media more effectively to humanize their offices and engage with their respective communities. The virtual event offers live, 45-minute presentations by experts in the industry who will provide key information and guidance designed to help those operating in the public sector develop an effective social media strategy. Topics covered will help attendees identify and build the foundations of a sustainable,…

Continue Reading

WednesdayDec 01, 2021 1:19 pm

NetworkNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Partners with Giant Eagle to Open Hearing Screening Kiosks

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, is partnering with Giant Eagle Inc. to install INND hearing kiosks in supermarkets located throughout Pennsylvania and Ohio. A grocery and pharmacy chain, Giant Eagle is one of the country’s largest retailers. The agreement calls for InnerScope to deploy its proprietary hearing kiosks in six locations initially, with more planned; Giant Eagle has more than 470 locations in Pennsylvania, Ohio, West Virginia, Maryland and Indiana. The kiosks allow Giant Eagle customers to easily and quickly self-check their hearing and obtain instant results. Customers can…

Continue Reading